治疗持续性异常性面部疼痛的阿米提林 - 珀菲纳治疗:从一个回顾性研究的翻译视角
Maurizio Marchesini1, Giulia Topi2,3, Cesare Bonezzi4
1Department of Anesthesia and Pain Medicine, Mater Olbia Hospital, Olbia, Italy.
Journal of anesthesia, analgesia and critical care
|December 19, 2024
概括
这项研究发现,结合阿米特利普提林和珀菲纳可显著减少疼痛,并改善了患有持久性异常性面部疼痛 (PIFP) 的患者的生活质量. 这种组合疗法为PIFP管理提供了一个有前途的新治疗选择.
科学领域:
- 神经学 神经学
- 疼痛管理 疼痛管理
- 药理学 药理学是指药理学的学科.
背景情况:
- 持久性异常性面部疼痛 (PIFP) 存在诊断和治疗方面的挑战,目前的治疗方法缺乏明确的标准.
- 阿米特利普提林是PIFP的第一线治疗方法,但通常表现出有限的有效性.
- 新兴研究强调了多巴胺在面部疼痛中的作用,这表明了新的治疗点.
研究的目的:
- 追溯评估阿米特利普提林 - 珀费纳组合在治疗严重PIFP时的疗效.
- 评估这种治疗对疼痛强度,发作频率和生活质量的影响.
主要方法:
- 对31名患有严重PIFP的患者进行了回顾性分析,这些患者接受了阿米二林-百芬 (10/2至20/4毫克) 治疗.
- 测量结果包括数值评分表 (NRS) 疼痛,发作次数和SF-36生活质量问卷.
- 对比了治疗前和治疗后的数据.
主要成果:
- 观察到NRS平均疼痛得分 (p<0.001) 和NRS最大疼痛得分显著降低.
- 每周发作的中位数显著下降 (p<0.001).
- 在SF-36问卷中,生活质量和身体功能得分有所改善 (p<0.001).
结论:
- 阿米特里普提林 - 珀费纳组合显示,PIFP患者的疼痛,发作频率和生活质量显著改善.
- 虽然样本规模很小,但研究结果表明,这种组合是PIFP的潜在有效和耐受良好治疗方法.
- 需要进一步的研究,以充分阐明多巴胺基通路在疼痛调节中的作用以及这种治疗有效性的基础机制.
相关概念视频
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
303
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
303
Analgesia and Pain Management
496
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
496
Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194


